Breast cancer case using tamoxifen during pregnancy: a case report and literature review
DOI:
https://doi.org/10.52981/sjms.v12i2.1330Keywords:
Breast cancer, Tamoxifen, Teratogenic effectsAbstract
This is a case of 32 years old nulliparous female who was diagnosed in November 2004 as a case of carcinoma of the right breast , luminal A , (Estrogen Receptor positive Progesterone receptor negative, Her 2 negative, Ki67 10 %), poorly differentiated invasive ductal cancer, TNM stage,T2 N0 MO. She had a wide local excision and axillary clearance. As she is a case of low risk early stage luminal A breast cancer; she was not given chemotherapy, instead she had a course of external irradiation and was put on Tamoxifen (Astra Zeneca, 20 mg daily), and was advised not to get pregnant during this treatment, but she got pregnant and delivered normally a healthy infant, although Tamoxifen is potentially teratogenic.
References
[1] A. Elamin, M. E. Ibrahim, D. Abuidris, K. E. H. Mohamed, and S. I. Mohammed, “Part I: Cancer in Sudan-burden, distribution, and trends breast, gynecological, and prostate cancers,” Cancer Medicine, vol. 4, no. 3, pp. 447–456, 2015.
[2] T. T. White, “Carcinoma of the Breast and Pregnancy,” Annals of Surgery, vol. 139, o. 1, pp. 9–18, 1954.
[3] T. Iguchi, M. Hirokawa, and N. Takasugi, “Occurence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen,” Toxicology, vol. 42, no. 1, pp. 1–11, 1986.
[4] K. Tewari, R. G. Bonebrake, T. Asrat, and A. M. Shanberg, “Ambiguous genitalia in infant exposed to tamoxifen in utero,” Lancet, vol. 350, no. 9072, p. 183, 1997.
[5] S. L. Cullins, G. Pridjian, and C. M. Sutherland, “Goldenhar’s Syndrome Associated With Tamoxifen Given to the Mother During Gestation,” JAMA: The Journal of the American Medical Association, vol. 271, no. 24, pp. 1905–1906, 1994.
[6] J. C. Berger and C. L. Clericuzio, “Pierre robin sequence associated with first trimester fetal tamoxifen exposure,” American Journal of Medical Genetics, Part A, vol. 146, no. 16, pp. 2141–2144, 2008.
[7] B. Geert, H. Denys, O. de Wever, V. Cocquyt, and R. van den Broeck, “Use of tamoxifen before and during pregnancy,” Oncologist, vol. 16, no. 11, pp. 1547–1551, 2011.
[8] K. Koizumi and T. Aono, “Pregnancy after combined treatment with bromocriptine and tamoxifen in two patients with pituitary prolactinomas,” Fertility and Sterility, vol. 46, no. 2, pp. 312–314, 1986.
[9] R. J. Isaacs, W. Hunter, and K. Clark, “Tamoxifen as systemic treatment of advanced breast cancer during pregnancy - Case report and literature review,” Gynecologic Oncology, vol. 80, no. 3, pp. 405–408, 2001.
[10] B. Geert, H. Denys, O. de Wever, V. Cocquyt, and R. van den Broeck, “Use of tamoxifen before and during pregnancy,” Oncologist, vol. 16, no. 11, pp. 1547–1551, 2011.
[11] S. Clark, “Prophylactic tamoxifen,” The Lancet, vol. 342, no. 8864, p. 168, 1993.
[12] E. Koca, T. Y. Kuzan, T. Babacan, I. H. Turkbeyler, F. Sarici, and K. Altundag, “Safety of tamoxifen during pregnancy: 3 case reports and review of the literature,” Breast Care, vol. 8, no. 6, pp. 453–454, 2013.
[2] T. T. White, “Carcinoma of the Breast and Pregnancy,” Annals of Surgery, vol. 139, o. 1, pp. 9–18, 1954.
[3] T. Iguchi, M. Hirokawa, and N. Takasugi, “Occurence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen,” Toxicology, vol. 42, no. 1, pp. 1–11, 1986.
[4] K. Tewari, R. G. Bonebrake, T. Asrat, and A. M. Shanberg, “Ambiguous genitalia in infant exposed to tamoxifen in utero,” Lancet, vol. 350, no. 9072, p. 183, 1997.
[5] S. L. Cullins, G. Pridjian, and C. M. Sutherland, “Goldenhar’s Syndrome Associated With Tamoxifen Given to the Mother During Gestation,” JAMA: The Journal of the American Medical Association, vol. 271, no. 24, pp. 1905–1906, 1994.
[6] J. C. Berger and C. L. Clericuzio, “Pierre robin sequence associated with first trimester fetal tamoxifen exposure,” American Journal of Medical Genetics, Part A, vol. 146, no. 16, pp. 2141–2144, 2008.
[7] B. Geert, H. Denys, O. de Wever, V. Cocquyt, and R. van den Broeck, “Use of tamoxifen before and during pregnancy,” Oncologist, vol. 16, no. 11, pp. 1547–1551, 2011.
[8] K. Koizumi and T. Aono, “Pregnancy after combined treatment with bromocriptine and tamoxifen in two patients with pituitary prolactinomas,” Fertility and Sterility, vol. 46, no. 2, pp. 312–314, 1986.
[9] R. J. Isaacs, W. Hunter, and K. Clark, “Tamoxifen as systemic treatment of advanced breast cancer during pregnancy - Case report and literature review,” Gynecologic Oncology, vol. 80, no. 3, pp. 405–408, 2001.
[10] B. Geert, H. Denys, O. de Wever, V. Cocquyt, and R. van den Broeck, “Use of tamoxifen before and during pregnancy,” Oncologist, vol. 16, no. 11, pp. 1547–1551, 2011.
[11] S. Clark, “Prophylactic tamoxifen,” The Lancet, vol. 342, no. 8864, p. 168, 1993.
[12] E. Koca, T. Y. Kuzan, T. Babacan, I. H. Turkbeyler, F. Sarici, and K. Altundag, “Safety of tamoxifen during pregnancy: 3 case reports and review of the literature,” Breast Care, vol. 8, no. 6, pp. 453–454, 2013.
Downloads
Published
2021-08-23
Issue
Section
Original Articles
